+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Three-month neoadjuvant hormonal therapy before radical prostatectomy: A 7-year follow-up of a randomized controlled trial



Three-month neoadjuvant hormonal therapy before radical prostatectomy: A 7-year follow-up of a randomized controlled trial



BJU International 90(6): 561-566



Objective: To describe the outcome, assessed as the level of prostate specific antigen (PSA), of a mature (more than half the events recorded) prospective randomized study with a median follow-up of 82 months of neoadjuvant hormonal therapy before radical prostatectomy, as this has been suggested to decrease the rate of positive surgical margins (i.e. provide greater potential to completely excise the tumour). Patient and methods: From December 1991 to March 1994, 126 patients with clinically localized prostate cancer were randomized between direct radical prostatectomy or a 3-month course of a gonadotrophin-releasing hormone analogue before surgery. The patients were followed by PSA determinations and a value of >0.5 ng/mL used to define progression. Results: The incidence of positive surgical margins decreased from 45.5% to 23.6% (P=0.016) with hormone treatment. Despite this there was no difference in PSA progression-free survival at the last follow-up; it was 51.5% for those undergoing radical prostatectomy only and 49.8% for those who received hormonal pre-treatment (P=0.588). Conclusions: Three months of neoadjuvant hormonal therapy before radical prostatectomy offers no benefit to the patient and cannot be recommended for routine clinical use.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 011567467

Download citation: RISBibTeXText

PMID: 12230618

DOI: 10.1046/j.1464-410x.2002.02982.x


Related references

Long-term follow-up of 3-month neoadjuvant hormone therapy before radical prostatectomy in a randomized trial. Bju International 105(2): 185-190, 2010

4-Year follow-up results of a European prospective randomized study on neoadjuvant hormonal therapy prior to radical prostatectomy in T2-3N0M0 prostate cancer. European Urology 38(6): 706-713, 2000

Randomized comparative study of 3 versus 8-month neoadjuvant hormonal therapy before radical prostatectomy: Biochemical and pathological effects. Journal of Urology 166(2): 500-507, 2001

Preliminary results of a prospective randomized study comparing radical prostatectomy versus radical prostatectomy associated with neoadjuvant hormonal combination therapy in T2-3 N0 M0 prostatic carcinoma. The European Study Group on Neoadjuvant Treatment of Prostate Cancer. Urology 49(3a Suppl): 65-69, 1997

4-Year follow-up results of a European prospective randomized study on neoadjuvant hormonal therapy prior to radical prostatectomy in T2-3N0M0 prostate cancer. European Study Group on Neoadjuvant Treatment of Prostate Cancer. European Urology 38(6): 706-713, 2000

A randomized trial of neoadjuvant androgen withdrawal therapy prior to radical prostatectomy 24 month post-treatment PSA results. Journal of Urology 157(4 Suppl. ): 92, 1997

Randomized comparative study of 3 vs 8 months of neoadjuvant hormonal therapy prior to radical prostatectomy 3 year PSA recurrence rates. Journal of Urology 169(4 Suppl.): 179, 2003

Preliminary results of a prospective randomized study comparing radical prostatectomy versus radical prostatectomy associated with neoadjuvant hormonal combination therapy in T23 N0 M0 prostatic carcinoma. Urology 49(3-Supp-S1): 65-69, 1997

Multicenter randomized comparative study of radical prostatectomy versus 3 and 6 months of neoadjuvant hormonal therapy prior to radical prostatectomy in stage B and C prostate cancer. Journal of Urology 163(4 Suppl ): 292, 2000

Preliminary results of a prospective randomized study comparing radical prostatectomy versus radical prostatectomy associated with neoadjuvant hormonal combination therapy in T-2-3 N-o M-o prostatic carcinoma. Urology 49(Suppl. 3A): 65-69, 1997

Radical prostatectomy with and without neoadjuvant hormonal treatment A 6 year follow-up. European Urology 39(Suppl 5): 137, 2001

Neoadjuvant hormonal therapy before radical prostatectomy decreases the number of positive surgical margins in stage T2 prostate cancer: Interim results of a prospective randomized trial. Journal of Urology 154(2 Part 1): 429-434, 1995

Neoadjuvant cyproterone acetate therapy prior to radical prostatectomy reduces tumour burden and margin positivity without altering 6 and 12 month post-treatment PSA Results of a randomized trial. Journal of Urology 155(5 Suppl. ): 399A, 1996

8-month neoadjuvant hormonal therapy before radical prostatectomy for high-risk prostate cancer. Nihon Hinyokika Gakkai Zasshi. Japanese Journal of Urology 97(5): 712-718, 2006

Comparative study of the impact of 3-versus 8-month neoadjuvant hormonal therapy on outcome of laparoscopic radical prostatectomy. Journal of Cancer Research and Clinical Oncology 133(8): 555-562, 2007